The relationship between brain metastasis and HER2 expression status in gastric cancer.
Brain metastasis
Gastric cancer
Human epidermal growth factor 2 amplification
SEER database
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
24 Aug 2023
24 Aug 2023
Historique:
received:
26
06
2023
accepted:
08
08
2023
medline:
25
8
2023
pubmed:
25
8
2023
entrez:
24
8
2023
Statut:
aheadofprint
Résumé
Brain metastasis (BM) in gastric cancer (GC) is underestimated, and human epidermal growth factor receptor 2 (HER2) overexpression is a durable poor prognostic factor. We explored the relationship between the two and made a survival analysis. HER2 expression and BM status were collected from GC patients who were diagnosed between December 2009 and May 2021. We collected GC patients diagnosed between 2010 and 2016 from the SEER database. The primary endpoint was survival from the diagnosis of BM. Multivariable logistic regression was used to determine potential risk factors of BM at diagnosis in SEER database. Survival analysis was performed using the Kaplan-Meier method. There were 513 HER2-positive GC patients, including 16 (3.1%) with BM. Among 38 brain metastasis GC patients we collected, 16 (42.1%) patients were HER2 positive. We collected 34,199 GC patients from the SEER database and there were 260 (0.76%) patients with BM at diagnosis. GC patients that are male, white, of younger age, with primary lesions located in the proximal stomach or with distant lymph nodes, liver, bone, or lung metastasis are more likely to develop BM. The median overall survival time from diagnosis of BM was 12.73 months, and the survival time from brain metastasis of HER2-positive patients was numerically shorter, though the difference was not significant (5.30 months vs.16.13 months, P = 0.28.) CONCLUSION: The incidence of BM in patients with HER2-positive gastric cancer is 4.08 times higher than that in general patients. The median overall survival time from BM is shorter for HER2-positive patients.
Sections du résumé
BACKGROUND
BACKGROUND
Brain metastasis (BM) in gastric cancer (GC) is underestimated, and human epidermal growth factor receptor 2 (HER2) overexpression is a durable poor prognostic factor. We explored the relationship between the two and made a survival analysis.
METHODS
METHODS
HER2 expression and BM status were collected from GC patients who were diagnosed between December 2009 and May 2021. We collected GC patients diagnosed between 2010 and 2016 from the SEER database. The primary endpoint was survival from the diagnosis of BM. Multivariable logistic regression was used to determine potential risk factors of BM at diagnosis in SEER database. Survival analysis was performed using the Kaplan-Meier method.
RESULT
RESULTS
There were 513 HER2-positive GC patients, including 16 (3.1%) with BM. Among 38 brain metastasis GC patients we collected, 16 (42.1%) patients were HER2 positive. We collected 34,199 GC patients from the SEER database and there were 260 (0.76%) patients with BM at diagnosis. GC patients that are male, white, of younger age, with primary lesions located in the proximal stomach or with distant lymph nodes, liver, bone, or lung metastasis are more likely to develop BM. The median overall survival time from diagnosis of BM was 12.73 months, and the survival time from brain metastasis of HER2-positive patients was numerically shorter, though the difference was not significant (5.30 months vs.16.13 months, P = 0.28.) CONCLUSION: The incidence of BM in patients with HER2-positive gastric cancer is 4.08 times higher than that in general patients. The median overall survival time from BM is shorter for HER2-positive patients.
Identifiants
pubmed: 37620706
doi: 10.1007/s12094-023-03306-2
pii: 10.1007/s12094-023-03306-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Innovative Research Group Project of the National Natural Science Foundation of China
ID : 82172748
Organisme : Innovative Research Group Project of the National Natural Science Foundation of China
ID : 82073377
Organisme : Innovative Research Group Project of the National Natural Science Foundation of China
ID : 81772587
Organisme : Natural Science Foundation of Guangdong Province for Distinguished Young Scholars
ID : 2021A1515012439
Informations de copyright
© 2023. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).
Références
Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol. 2020;18(3):534–42. https://doi.org/10.1016/j.cgh.2019.07.045 .
doi: 10.1016/j.cgh.2019.07.045
pubmed: 31362118
Yu M, Zheng HC, Xia P, Takahashi H, Masuda S, Takano Y, et al. Comparison in pathological behaviours & prognosis of gastric cancers from general hospitals between China & Japan. Indian J Med Res. 2010;132:295–302.
pubmed: 20847376
Go PH, Klaassen Z, Meadows MC, Chamberlain RS. Gastrointestinal cancer and brain metastasis: a rare and ominous sign. Cancer. 2011;117(16):3630–40. https://doi.org/10.1002/cncr.25940 .
doi: 10.1002/cncr.25940
pubmed: 21319152
Qiu MZ, Shi SM, Chen ZH, Yu HE, Sheng H, Jin Y, et al. Frequency and clinicopathological features of metastasis to liver, lung, bone, and brain from gastric cancer: a SEER-based study. Cancer Med. 2018;7(8):3662–72. https://doi.org/10.1002/cam4.1661 .
doi: 10.1002/cam4.1661
pubmed: 29984918
pmcid: 6089142
Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52(7):797–805. https://doi.org/10.1111/j.1365-2559.2008.03028.x .
doi: 10.1111/j.1365-2559.2008.03028.x
pubmed: 18422971
Hsu JT, Chen TC, Tseng JH, Chiu CT, Liu KH, Yeh CN, et al. Impact of HER-2 overexpression/amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patients. Oncologist. 2011;16(12):1706–13. https://doi.org/10.1634/theoncologist.2011-0199 .
doi: 10.1634/theoncologist.2011-0199
pubmed: 22143936
pmcid: 3248769
Sheng WQ, Huang D, Ying JM, Lu N, Wu HM, Liu YH, et al. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann Oncol. 2013;24(9):2360–4. https://doi.org/10.1093/annonc/mdt232 .
doi: 10.1093/annonc/mdt232
pubmed: 23788757
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. https://doi.org/10.1016/S0140-6736(10)61121-X .
doi: 10.1016/S0140-6736(10)61121-X
pubmed: 20728210
Berghoff A, Bago-Horvath Z, De Vries C, Dubsky P, Pluschnig U, Rudas M, et al. Brain metastases free survival differs between breast cancer subtypes. Br J Cancer. 2012;106(3):440–6. https://doi.org/10.1038/bjc.2011.597 .
doi: 10.1038/bjc.2011.597
pubmed: 22233926
pmcid: 3273356
Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49. https://doi.org/10.1111/apm.1965.64.1.31 .
doi: 10.1111/apm.1965.64.1.31
pubmed: 14320675
Minisini AM, Moroso S, Gerratana L, Giangreco M, Iacono D, Poletto E, et al. Risk factors and survival outcomes in patients with brain metastases from breast cancer. Clin Exp Metastasis. 2013;30(8):951–6. https://doi.org/10.1007/s10585-013-9594-5 .
doi: 10.1007/s10585-013-9594-5
pubmed: 23775210
Ahn HK, Park YH, Lee SJ, Park S, Maeng CH, Park W, et al. Clinical implication of time to brain metastasis (TTBM) according to breast cancer subtypes. Springerplus. 2013;2(1):136. https://doi.org/10.1186/2193-1801-2-136 .
doi: 10.1186/2193-1801-2-136
pubmed: 23667803
pmcid: 3647103
Kuksis M, Gao Y, Tran W, Hoey C, Kiss A, Komorowski AS, et al. The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. Neuro Oncol. 2021;23(6):894–904. https://doi.org/10.1093/neuonc/noaa285 .
doi: 10.1093/neuonc/noaa285
pubmed: 33367836
Blay C, Chiforeanu DC, Boucher E, Cabillic F, Desgrippes R, Leconte B, et al. Incidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma. Acta Oncol. 2015;54(10):1833–5. https://doi.org/10.3109/0284186X.2015.1011757 .
doi: 10.3109/0284186X.2015.1011757
pubmed: 25753188
Feilchenfeldt J, Varga Z, Siano M, Grabsch HI, Held U, Schuknecht B, et al. Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). Br J Cancer. 2015;113(5):716–21. https://doi.org/10.1038/bjc.2015.279 .
doi: 10.1038/bjc.2015.279
pubmed: 26313663
pmcid: 4559836
Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014. https://doi.org/10.1093/jnci/dju055 .
doi: 10.1093/jnci/dju055
pubmed: 24777111
pmcid: 4580552
Limon D, Gal O, Gordon N, Katz L, Perl G, Purim O, et al. Brain metastasis in gastroesophageal adenocarcinoma and HER2 status. J Neurooncol. 2018;138(2):315–20. https://doi.org/10.1007/s11060-018-2798-4 .
doi: 10.1007/s11060-018-2798-4
pubmed: 29429124
Hosonaga M, Saya H, Arima Y. Molecular and cellular mechanisms underlying brain metastasis of breast cancer. Cancer Metastasis Rev. 2020;39(3):711–20. https://doi.org/10.1007/s10555-020-09881-y .
doi: 10.1007/s10555-020-09881-y
pubmed: 32399646
pmcid: 7497304
Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008;68(14):5878–87. https://doi.org/10.1158/0008-5472.CAN-08-0380 .
doi: 10.1158/0008-5472.CAN-08-0380
pubmed: 18632642
Blazquez R, Wlochowitz D, Wolff A, Seitz S, Wachter A, Perera-Bel J, et al. PI3K: A master regulator of brain metastasis-promoting macrophages/microglia. Glia. 2018;66(11):2438–55. https://doi.org/10.1002/glia.23485 .
doi: 10.1002/glia.23485
pubmed: 30357946
Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16(2):273–8. https://doi.org/10.1093/annonc/mdi064 .
doi: 10.1093/annonc/mdi064
pubmed: 15668283
Saeki H, Oki E, Kashiwada T, Arigami T, Makiyama A, Iwatsuki M, et al. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). Eur J Cancer. 2018;105:41–9. https://doi.org/10.1016/j.ejca.2018.09.024 .
doi: 10.1016/j.ejca.2018.09.024
pubmed: 30391779
Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer. 2011;11(5):352–63. https://doi.org/10.1038/nrc3053 .
doi: 10.1038/nrc3053
pubmed: 21472002
pmcid: 7351203
Kodack DP, Chung E, Yamashita H, Incio J, Duyverman AM, Song Y, et al. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proc Natl Acad Sci U S A. 2012;109(45):E3119–27. https://doi.org/10.1073/pnas.1216078109 .
doi: 10.1073/pnas.1216078109
pubmed: 23071298
pmcid: 3494882
Wolstenholme V, Hawkins M, Ashley S, Tait D, Ross G. HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients. Breast. 2008;17(6):661–5. https://doi.org/10.1016/j.breast.2008.04.006 .
doi: 10.1016/j.breast.2008.04.006
pubmed: 18571923
Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, et al. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022;72(2):165–82. https://doi.org/10.3322/caac.21705 .
doi: 10.3322/caac.21705
pubmed: 34767258
Yoshida J, Sugiyama K, Satoh M, Shiraishi K, Nishibori R, Kitagawa C. Efficacy of trastuzumab deruxtecan in an advanced gastric cancer patient with brain metastasis. Curr Probl Cancer. 2021;45(6):100757. https://doi.org/10.1016/j.currproblcancer.2021.100757 .
doi: 10.1016/j.currproblcancer.2021.100757
pubmed: 33892964